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Abstract
Background: For men and women, taller height is associated with increased risk of all
cancers combined. For colorectal cancer (CRC), it is unclear whether the differential asso-
ciation of height by sex is real or is due to confounding or bias inherent in observational
studies. We performed a Mendelian randomization study to examine the association be-
tween height and CRC risk.
Methods: To minimize confounding and bias, we derived a weighted genetic risk score pre-
dicting height (using 696 genetic variants associated with height) in 10226 CRC cases and
10 286 controls. Logistic regression was used to estimate odds ratios (OR) and 95% confidence
intervals (95% CI) for associations between height, genetically predicted height and CRC.
Results: Using conventional methods, increased height (per 10-cm increment) was asso-
ciated with increased CRC risk (OR¼1.08, 95% CI¼1.02–1.15). In sex-specific analyses,
height was associated with CRC risk for women (OR¼1.15, 95% CI¼1.05–1.26), but not
men (OR¼ 0.98, 95% CI¼ 0.92–1.05). Consistent with these results, carrying greater num-
bers of (weighted) height-increasing alleles (per 1-unit increase) was associated with
higher CRC risk for women and men combined (OR¼ 1.07, 95% CI¼1.01–1.14) and for
women (OR¼1.09, 95% CI¼1.01–1.19). There was weaker evidence of an association for
men (OR¼1.05, 95% CI¼0.96–1.15).
Conclusion: We provide evidence for a causal association between height and CRC for
women. The CRC-height association for men remains unclear and warrants further inves-
tigation in other large studies.
Key words: Body height, colorectal cancer, epidemiology
Key Messages
• Observational studies have consistently reported an association between height and risk of colorectal cancer for
women; however, the association of height with colorectal cancer for men is unclear.
• We used genetically determined height to re-examine whether the association between height and risk of colorectal
cancer is causal.
• The results strongly suggest that height is causally associated with colorectal cancer risk for women.
• There is weaker evidence for the association between height and increased risk of colorectal cancer for men.
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Introduction
Greater attained adult height has been consistently asso-
ciated with higher risk of developing colorectal cancer
(CRC);1 however, the results from these epidemiological
studies have suggested that this association may be stron-
ger for women than for men.2–12 It is possible that the
positive association observed between height and CRC
risk for women is due to residual confounding by factors
that are difficult to measure and control for using conven-
tional epidemiological methods. Conversely, misclassifi-
cation of height may partly attenuate a true positive and
causal association between height and CRC risk for men.
Assuming a causal association exists, since shorter men
may tend to over-report their height more than do taller
men,13 and those shorter men would have inherently
lower CRC risk, then their over-reporting of height
would cause them to migrate upward to taller height cate-
gories. This influx of men inherently at lower risk of
CRC, due to their shorter height, would lower the rate of
CRC in this otherwise higher risk group. On the other
hand, women tend to more accurately report their height,
potentially explaining why such bias may not occur
(or may be less) for women. Height may be a marker of
biological factors (e.g. steroid hormones and other
growth factors) or a marker of factors such as nutrition
and energy intake that could be causally associated with
the risk of developing CRC; however, these potential
biases hamper the interpretation of findings from obser-
vational studies.
Mendelian randomization offers an alternative
method to investigate the association between height and
the risk of CRC. An advantage of using Mendelian
randomization and instrumental variable methods to inves-
tigate this link is that height is highly genetically deter-
mined.14 Mendelian randomization uses instrumental
variables (e.g. genetic variants that proxy for directly
measured environmental, behavioural or social factors) to
make causal inferences about the relationship between a
risk factor and an outcome. Using height-related genetic
variants to predict height, the instrumental variable ap-
proach can help overcome issues of confounding, recall
bias and reverse causality inherent in observational stud-
ies(for example, where observational associations for
height may be confounded by early life exposures, diet or
reporting bias) and the resulting risk estimate should be a
better estimate of the true causal effect of height on CRC
risk.15–17
Here, we used genetic variation related to height and
instrumental variable methods to reinvestigate the height-
CRC association. We examined the association for all
persons combined and for men and women separately to
clarify sex-specific associations.
Methods
All participants provided written, informed consent and
studies were approved by their respective institutional re-
view boards.
Study population and sources of data
We used epidemiological and genetic data from 10 226
CRC cases and 10 286 population-based controls of
European ancestry from 11 studies (6 cohort studies and 5
case-control studies) participating in the Genetics and
Epidemiology of Colorectal Cancer Consortium
(GECCO) and Colon Cancer Family Registry (C-CFR)
(Supplementary Table 1, available as Supplementary
data at IJE online). Full details on the consortium
(GECCOþC-CFR) have been published elsewhere.18 The
11 studies included in our analysis were the Health
Professionals Follow-up Study (HPFS);19 Nurses’ Health
Study (NHS);20 Physician’s Health Study (PHS);21
Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial (PLCO);22 VITamins And Lifestyle Study (VITAL);23
Women’s Health Initiative (WHI);24 Colon-Cancer Family
Registry (C-CFR);25 Ontario Familial Colon Cancer
Registries (OFCCR);26 Diet, Activity and Lifestyle Survey
(DALS);27,28 Postmenopausal Hormone Study (PMH-
CCFR);29 and Darmkrebs: Chancen der Verhütungdurch
Screening (DACHS).30 There was no overlap of partici-
pants between the 11 studies.
Outcomes
CRC cases were men and women with histologically con-
firmed (in each study by medical records, pathological re-
ports or death certificates) invasive adenocarcinoma of the
colon or rectum (International Classification of Disease
Code, 9th revision: 153-154). We calculated risk estimates
associated with height for CRC overall and separately for
colon and rectal cancers.
Genotyping and the instrumental variable
for height
Full details on genotyping, quality assurance/quality con-
trol and imputation have been previously reported.18 In
brief, to avoid confounding by population stratification,
we used principal components analysis to restrict our ana-
lyses to individuals of European ancestry.31 Genotyped sin-
gle nucleotide polymorphisms (SNPs) were excluded based
on call rate (<98%), lack of Hardy–Weinberg equilibrium
in controls (P< 1 104) and low minor allele frequency
(MAF 1%). Because imputation of genotypes is estab-
lished as standard practice in the analysis of genotype array
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data, we imputed the autosomal SNPs of all studies to the
Utah residents with Northern and Western European an-
cestry from the Centre d’Etude du Polymorphisme Humain
(CEPH) collection (CEU) population in HapMap II.
Imputed SNPs were restricted based on MAF and overall
imputation accuracy (R2> 0.3).
A recent genome-wide association study (GWAS)
of height conducted by the Genetic Investigation of
ANthropometric Traits (GIANT) consortium identified 697
genetic variants associated with height at genome-wide sig-
nificance (P< 5 108).32 We excluded one variant associ-
ated with height in Ref #32 due to low imputation quality
(rs17499117, mean R2¼ 0.27, range 0.14–0.36).
We created a weighted genetic risk score predicting
height by summing the number of height-increasing alleles
in each person across the 696 variants. For each variant,
we assigned participants a value of 0, 1 or 2 for carrying
zero (wild-type homozygous), one (heterozygous) or two
(homozygous for the risk allele) alleles associated with
greater height. When a variant was imputed, each partici-
pant was assigned a value between 0 and 2. Each variant in
the genetic risk score was weighted by the per-allele change
in height (the increase in cm per one additional risk allele)
reported in the GIANT GWAS (i.e. we used external
weights in the risk score).32
Covariates
The individual studies collected information on demo-
graphic and lifestyle factors through either in-person inter-
views or structured self-completed health and lifestyle
questionnaires. The data harmonization process for the
consortium has been described in full previously.33
Statistical analysis
We examined associations between height and risks of
CRC overall, and its two components separately (colon
cancer and rectal cancer) for women and men combined,
and then separately for women and men. All statistical
analyses were performed using Stata 13.0 (StataCorp LP,
College Station, TX, USA).
First, we assessed associations with height (continuous
and in sex-specific quartiles) using a two-step meta-ana-
lytic approach. In the first stage, study-specific odds ratios
(OR) and corresponding 95% confidence intervals (95%
CI) were estimated using logistic regression models, ad-
justed for age (continuous), sex, family history of CRC
(no, yes), history of diabetes (no, yes), smoking status
(never, former, current), aspirin or non-aspirin non-ster-
oidal anti-inflammatory drugs (NSAID) use (no, yes), con-
sumption of vegetables (sex-specific quartiles),
consumption of red meat (sex-specific quartiles) and meno-
pause hormone therapy (Women only; no, yes). To esti-
mate the independent effect for height, instead of adjusting
for weight or body mass index (BMI) which are associated
with the outcome and are appreciably correlated with
height, we adjusted for a weight-for-height variable
(W/Hx) for such values of x that W/Hx was highly corre-
lated with weight (Pearson correlation coefficient, r, close
to 1) but not correlated with height (r close to 0). In our
population, the optimal factor was x¼1.8 for all, x¼1.5
for women and x¼ 1.7 for men. We considered weight,
smoking status, family history of cancer, diabetes, use of
aspirin or NSAIDs, fruit, vegetable, processed meat and
red meat consumption, sedentary lifestyle and menopause
hormone therapy as potential confounding variables.
Variables were retained in the final fully adjusted models if
they were associated with CRC risk after mutual adjust-
ment for other risk factors (P< 0.05). In the second step,
the study-specific adjusted ORs were pooled to create a
summary OR, using random effects models.34 We used the
I2 statistic to assess the heterogeneity between studies.35 I2
values of 25%, 50% and 75% were used as evidence of
low, moderate or high levels of heterogeneity, respectively.
Using controls only (representing the population from
which the cases arose), we then examined the association
between the weighted genetic risk score and height in each
study and meta-analysed the results. In the first step, study-
specific regression coefficients and corresponding 95% CIs
were estimated using linear regression models, adjusted for
age and the first three principal components that reflected
the population structure to control for population stratifi-
cation. In the second step, the study-specific regression
coefficients were pooled to create a summary coefficient
using random effects models. The F-statistic and R2 for the
regression of height on genetically predicted height (i.e.,
the weighted genetic risk score) were obtained; an F-
statistic> 10 suggests the genetic instrument is associated
with the exposure and is unlikely to suffer from weak in-
strument bias.36
Third, we examined whether genetically
determined height was directly associated with risk of
CRC, colon cancer and rectal cancer. We used the same
two-step meta-analytic approach: first, using logistic re-
gression models adjusted by age and the first three princi-
pal components to estimate study-specific ORs for the
associations between genetically determined height and
CRC, colon cancer and rectal cancer; and second, meta-
analysing the results (using random effects models) to gen-
erate summary ORs.
Finally, we used linear regression to estimate the associ-
ations of genetically determined height and height with a
set of potential confounders.
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Results
Characteristics of cases and controls included in this ana-
lysis are presented in Supplementary Tables 1 and 2 (avail-
able as Supplementary data at IJE online). All potential
confounders were associated with height and/or with risk
of CRC (Supplementary Tables 2 and 3, available as
Supplementary data at IJE online). The weighted genetic
risk score was largely not associated with factors that may
confound the observational association between height
and risk of CRC. Dietary factors were somewhat associ-
ated with the weighted genetic risk score, but associations
were not consistent across categories and tended to vary in
sex-specific analyses (Supplementary Table 3).
Height, CRC, colon cancer and rectal cancer
In a conventional covariate-adjusted analysis (Table 1 and
Figure 1A), a 10-cm increase in height was associated with
an 8% increase in the risk of CRC (95% CI¼ 1.02–1.15),
with moderate between-study heterogeneity (I2¼ 45%).
The point estimate was larger when we examined the asso-
ciation in studies involving measured height (OR per
10-cm increase in height¼1.12, 95% CI¼ 1.03–1.23) vs
studies involving self-reported height (OR per 10-cm in-
crease in height¼ 1.07, 95% CI¼ 1.00–1.16), although
the CIs overlapped. The observational association with
height did not vary according to cancer sub-site in the col-
orectum (Table 1). However, the observational associ-
ations differed by sex. Whereas height was associated with
risks of CRC, colon cancer and rectal cancer for women in
conventional covariate-adjusted analyses, there were no as-
sociations with height for men (Table 1).
Instrumental variable and height
When we regressed height on the weighted genetic risk score,
individuals carrying greater numbers of (weighted) height-
increasing alleles had higher attained adult height. For ex-
ample, persons in the highest quartile of the weighted genetic
risk score were 5.89cm taller on average than persons in the
lowest quartile. The association was homogeneous across
studies (Figure 1B). The weighted genetic risk scores were
strong instrumental variables for height (F-statistics: all, ad-
justed for sex, partial F-statistic¼1544; women, 916.4; men,
635.5) and the weighted genetic risk score explained 13.3%
(partial R2), 13.8% and 12.3% of the variation in height in
all persons, women and men, respectively.
Instrumental variable, CRC, colon cancer and
rectal cancer
We found evidence that persons carrying greater numbers
of (weighted) height-increasing alleles were at greater risk
for CRC (OR per 1-unit increase in the weighted genetic
risk score¼ 1.07, 95% CI 1.01-1.14; Table 2 and
Figure 1C). Corresponding ORs were 1.05 (95%
CI¼ 0.98–1.12) for colon cancer, and 1.09 (95%
CI¼ 0.98–1.20) for rectal cancer. Consistent with the con-
ventional covariate-adjusted analysis (Table 1), women car-
rying greater numbers of (weighted) height-increasing alleles
were at greater risk for CRC (OR per 1-unit increase in the
weighted genetic risk score¼ 1.09, 95% CI 1.01–1.19). In
contrast to the conventional covariate-adjusted analysis, we
found some evidence that men carrying greater numbers of
(weighted) height-increasing alleles have greater risk for
CRC (OR per 1-unit increase in the weighted genetic risk
score¼ 1.05, 95% CI 0.96–1.15). The point estimate for
men was of similar order and in the same direction as that
seen for women. We observed similar findings when we
examined separately colon and rectal cancers (Table 2).
Additionally adjusting for red and processed meats (and
other CRC risk factors) did not change the ORs for CRC,
colon cancer or rectal cancer associated with the weighted
genetic risk score.
Discussion
In this large population-based study, we used a Mendelian
randomization approach and genetically predicted height
to examine for the presence of a causal association between
height and CRC. Due to the study design, we did not how-
ever estimate the magnitude of this causal effect. The pri-
mary finding of this study was that greater height is
causally associated with increased risk of CRC. The evi-
dence was however somewhat weaker for men than for
women. In the analyses involving men and women com-
bined and those involving women only, the associations
with height and genetically predicted height were consist-
ent and demonstrated a strong causal association between
height and CRC. For men, the conventional covariate-ad-
justed and instrumental variables analyses found little or
weak evidence of an effect. However, because the point es-
timates and confidence intervals for men associated with
genetically predicted height were similar to those found for
women, it is possible that we did not find strong evidence
of a causal effect for men simply due to chance or lack of
statistical power.
Observational studies have consistently reported higher
risk of CRC for taller women. Conversely, an association
between height and the risk of CRC for men has been
observed in some, but not all, studies and the magnitude
of this association is generally lower than that for
women.2–12 Consistent with these observational associ-
ations, in our conventional covariate-adjusted analysis of
height and the risk of CRC, we found that greater height
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was associated with increased risk of CRC for women.
Height was not associated with CRC risk for men in this
study. It is possible that selective over-reporting of height
in men13 may explain the lack of association with CRC
risk in the conventional analyses. We found some evidence
to support this hypothesis with the observational associ-
ation greater in magnitude in studies involving measured
height compared with those involving self-reported height.
It is worth noting that whereas there was modest hetero-
geneity between the studies (both measured and self-re-
ported height studies) for the observational association
among women (I2¼48%), there was no evidence of het-
erogeneity in the analyses among men (I2¼ 0%); however,
only one of eight studies in the men-only analysis included
measured height. The same patterns of association were
seen for risk of colon and rectal cancers.
Using instrumental variable methods, genetically pre-
dicted height was associated with risk of CRC for women.
This novel finding provides strong support for a causal
association between height and CRC risk for women; how-
ever, the magnitude of this effect could not be estimated in
this study. The association between height and CRC risk
for men remains unclear. Our study provides little or weak
evidence for a causal association between height and CRC
risk for men. However, because the point estimate for men
associated with genetically predicted height was of similar
order and in the same direction as that seen for women, we
cannot completely rule out a causal association between
height and CRC for men.
Several mechanisms by which greater height may confer
higher risk of cancer have been proposed, and include
higher exposure to steroid hormones and other growth fac-
tors, leading to higher cell turnover and greater risk of ma-
lignant transformation.37 However, assuming height is
causally associated with CRC risk for women and not for
men, the mechanisms through which height would confer
an effect on CRC risk for women only are unknown.
Interestingly, although the relationships between adiposity,
Figure 1. (A) Summary odds ratio for the association between a 10-cm increase in height and the risk of CRC. (B) Summary estimate comparing Q4
with Q1 for the association between the weighted genetic risk score (quartiles) and height (continuous). (C) Summary odds ratio for the association
between a one-unit increase in the weighted genetic risk score and the risk of CRC.
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sex and risk of CRC are complex and unresolved, it has
been suggested in some studies that BMI and weight gain
are more strongly associated with CRC risk for men than
for women.38 Assuming this to be true, we can speculate
that the contrast between men and women for height and
adiposity may suggest different susceptibility periods to
cancer development due to positive energy balance. For ex-
ample, it is possible that positive energy balance early in
life, reflected by attained adult height, confers higher risk
of CRC for women, whereas positive energy balance later
in life, as reflected by higher BMI or greater weight gain,
confers higher risk of CRC for men. Sex is clearly a strong
modifier for the influence of body size on CRC risk and re-
quires further investigation in future studies.
The large sample size and homogeneous study popula-
tion are strengths of the present study. We were able to ad-
just our analyses for a standard set of harmonized
variables that may confound observational associations be-
tween height and CRC risk, and we found little evidence of
between-study heterogeneity. In the instrumental variable
analysis, we used multiple genetic variants to examine the
complex relationship between height and CRC risk.
Because genotype is randomly allocated at conception, as-
sociations between genetically determined height and CRC
risk are unlikely to be biased, confounded or affected by re-
verse causality. Additionally, the association between gen-
etically determined height and CRC risk is likely to reflect
the effect of lifelong exposure to greater height.
There are limitations to our study. Because our study
was restricted to participants of European descent, our re-
sults may not necessarily apply to other races. However,
this fact also minimizes the risk of population stratification
affecting the results of our instrumental variable analyses.
Mendelian randomization relies on three key assumptions.
First, that the instrumental variable is associated with
height. We derived a weighted genetic risk score predicting
height based on 696 genetic variants associated with
height. The weighted genetic risk score model compared
large numbers of people with large differences in genetic-
ally influenced height (e.g. almost 6 cm difference in height
between persons in the highest vs lowest quartile of the
score) and was a strong instrument for height (F-statis-
tics10), reducing the chance of weak instrument bias.
However, as the phenotypic variation in height explained
by the weighted genetic risk score was less than 14%, we
did not test the full spectrum of genetically influenced
height. The second assumption is that the instrumental
variable is not associated with potential confounders of the
conventional height-CRC association. The association be-
tween the genetic risk score and red and processed meats
was unexpected a priori, and may be due to chance.
Nonetheless, inclusion of these factors in the analyses of
genetically determined height and CRC did not change the
risk estimates. Finally, the third assumption, that no other
pathway exists between the instrumental variable and
CRC risk, is difficult to prove, and may be violated by plei-
otropy [e.g. through a joint mechanism, such as the insu-
lin-like growth factor (IGF) axis]. It is possible that a
number of the individual genetic variants used to derive
the weighted genetic risk score are associated with height
as well as other factors if height is causally associated with
these secondary traits (i.e. vertical pleiotropy).39 If the
weighted genetic risk score is associated with CRC through
biological factors related to height (e.g. the indirect effect,
mediated through a secondary trait) rather than directly
through height, this would still be the same pathway by
which the marker height affects CRC risk. Furthermore,
assuming the only pathway by which the variants are asso-
ciated with secondary traits is through height, our findings
hold in spite of the apparent pleiotropic association. A
variant may also be associated with multiple pathways
(horizontal pleiotropy), including those not involving
height.39 To the best of our knowledge, none of the 696
height variants used here have overly potent pleiotropic
Table 2. Summary odds ratios (OR) and 95% confidence intervals (CI) for the association between a 1-unit increase in the
weighted genetic risk score (the instrumental variable for height) and risk of colorectal cancer (CRC), colon cancer and rectal
cancera
Site All Women Men
Cases/
Controls
ORb (95% CI) I2 Cases/
Controls
ORb (95% CI) I2 Cases/
Controls
ORb (95% CI) I2
Colorectal cancer 10226/10286 1.07 (1.01–1.14) 0% 5644/5747 1.09 (1.01–1.19) 0% 4582/4539 1.05 (0.96–1.15) 0%
Colon cancer 6864/10286 1.05 (0.98–1.12) 0% 3922/5747 1.04 (0.95–1.14) 0% 2942/4539 1.06 (0.96–1.17) 0%
Rectal cancer 2365/10286 1.09 (0.98–1.20) 0% 1112/5747 1.05 (0.90–1.22) 0% 1253/4539 1.13 (0.98–1.31) 0%
Summary odds ratios were estimated using a random effects meta-analytical model.
aNot all cases from CRC analyses were included in the site-specific analyses (i.e. where we did not have site data for analysis).
bAdjusted for age (continuous) and the top three principal components of ancestry.
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effects and none was associated with CRC in recent
GWASs of CRC.18 Therefore, it seems unlikely that a sub-
stantial fraction of pleiotropic SNPs in the cumulative risk
score would explain the associations with height.
In conclusion, height was causally associated with CRC
risk; however, the sex-specific effects of height on CRC
risk require further investigation. This is one of the first
studies to use Mendelian randomization to reinvestigate
the observed association between height and cancer risk.
Our results show the value of instrumental variable meth-
ods to assess the existence of a causal association between
height and cancer risk.
Supplementary Data
Supplementary data are available at IJE online.
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